Research programme: dry eye syndrome therapy - arGentis LLC

Drug Profile

Research programme: dry eye syndrome therapy - arGentis LLC

Alternative Names: ARG 101(T); ARG 102(P); ARG 103; T4DE; T4DE - arGentis

Latest Information Update: 26 Nov 2015

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Argentis LLC
  • Developer arGentis Pharmaceuticals
  • Class Anabolic steroids; Androstenols; Erectile dysfunction therapies; Hormonal replacements; Small molecules; Testosterone congeners
  • Mechanism of Action Progesterone receptor agonists; Testosterone agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Dry eyes

Most Recent Events

  • 26 Nov 2015 Discontinued - Preclinical for Dry eyes in USA (Topical)
  • 24 May 2009 No development reported - Preclinical for Dry eyes in USA (Topical)
  • 16 Jan 2007 arGentis licenses transdermal progesterone in the treatment of Dry Eye Syndrome from Southern College of Optometry
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top